Pre COVID-19 pandemic no one could have imagined a pandemic of such magnitude could happen across the globe bringing the world to a halt. Evidently, the current sanitary situation and travelling restrictions across continents has brought onsite audits to a standstill. However, the qualification process cannot be compromised so what options do pharma companies have…

Some of the requirements to conduct on-site GMP audits are therefore clear, for example in Article 46(f) EU Directive 2001/83/EC:
“the holder of the manufacturing authorisation shall verify compliance by the manufacturer and distributors of active substances with good manufacturing practice and good distribution practices by conducting audits at the manufacturing and distribution sites…”

Some of the options incorporated by the authorities or even the marketing authorisation holders is to have a distant assessment through remote desktop audits either through video conferencing or an audio communication. In April 2020 the EMEA authorities have already devised a questionnaire (question and answer document) which broadly  addresses the remote distant assessment of manufacturer’s and cites examples of  audits which can be conducted. 

The pharmaceutical industry and marketing authorisation holders have little choice but to resort to remote desktop GMP verification. A distant assessment is therefore a possible way to assess manufacturer’s or CMO’s GMP compliance. The Qualified Person (QP) conducting desktop audit can clearly point out that distant assessments are not intended as a substitute for on-site inspections and that on-site inspections should be carried out as soon as circumstances permit. Decision should be based on an adequate, scientific and documented risk assessment.

For new sites too such distant assessments by the competent authorities can be an option and provisional GMP certificate can be issued based on the assessment outcome with a condition to allow the onsite GMP audits as soon as it becomes possible. Distant assessment and supplier qualification will certainly increase in the near future, but these qualifications cannot replace the onsite audit requirements.

Resources: 

Notice to stakeholder’s questions and answers on regulatory expectations for medicinal products for human use during the covid-19 pandemic: 

https://ec.europa.eu/health/sites/health/files/human-use/docs/guidance_regulatory_covid19_en.pdf



More News
Lynparza shows promise in preventing cancer recurrence
News · 16/06/2021

AstraZeneca and MSD’s Lynparza (olaparib) has shown efficacy in preventing cancer recurrence in patients with germline BRCA-mutated (gBRCAm) high-risk human epidermal growth factor receptor 2 (HER2)-negative early breast cancer.

READ MORE
Is ammonia the fuel of the future?
News · 15/06/2021

Ammonia saved the world once; it might do it again. A century ago, the world faced a looming food crisis. A booming population was pushing farmers to grow crops faster than nitrogen-fixing bacteria in the soil could keep up, and the South American deposits of guano and natural nitrates they applied as fertilizer were dwindling.

READ MORE
Lipids – The unsung vaccine component
News · 15/06/2021

Lipids are an unsung component in the two mRNA-based shots, the only vaccines to be approved so far in the US. Naked mRNA quickly degrades in the body and can trigger an unwanted immune reaction. To get the genetic material to its target cells, vaccine developers combine it with a mixture of several sophisticated lipids to form lipid nanoparticles, or LNPs. mRNA vaccine producers use a package of 4 lipids to formulate their LNPs

READ MORE
Short-lived romance: Pharma industry facing heat for Covid vaccine failures, greed
News · 01/06/2021

An unprecedented push to manufacture billions of doses this year alone has led to supply bottlenecks, putting firms such as Pfizer and AstraZeneca Plc in the firing line of angry government customers. Now the industry is taking heat for closely guarding its intellectual property.

READ MORE
Australian Vaccine First In World To Show Ability To Totally Block Covid-19 Virus Transmission
News · 01/06/2021

Australian company, Vaxine Pty Ltd, has developed a protein based COVID-19 vaccine that completely blocks virus transmission to non-immune individuals.

READ MORE
As consciousness about nutrition, health rises in post-COVID world, demand for Organic Food is set to surge
News · 01/06/2021

If one positive could be drawn out of the devastating global COVID 19 crisis, it is the fact that this calamitous pandemic has made people more conscious about the need for healthier lifestyles, nutrition as well as their environmental footprint.

READ MORE
India’s Covid crisis & its impact on Global Shipping
News · 01/06/2021

India’s devastating Covid-19 crisis is threatening operations at some of its biggest ports, raising concerns. The action could trigger shipping delays that reverberate through global supply chains.

READ MORE
Khaana Chahiye | Fighting Hunger in Mumbai
News · 19/05/2021

A team of driven, concerned, caring citizens who decided to make a difference!

READ MORE
Molnupiravir – An investigational antiviral treatment developed in oral dosage form to fight against coronavirus and future pandemics:
News · 03/05/2021

Over the last year, several drugs have either been developed or tested to treat coronavirus. Now there’s another new antiviral drug that’s showing some promise by demonstrating ability to stop SARS-CoV-2 transmission within 24 hour!

READ MORE